NCT02174432Phase 2, phase 3Completed

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Study sponsor: Trevi Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2017-09-03Actual
Enrollment · participants36Actual
Source updated2025-05-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.